Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Post Doctoral Fellow, Md Anderson Cancer Center, University of Texas Medical School, Houston 2010 - 2012
  • Post-Doctoral Fellow, Duke University 2006 - 2010
  • Ph.D., Duke University 2006
• 

  Duke Appointment History

  • Instructor, Temporary in the Department of Surgery, Surgery, Surgical Sciences, Surgery 2012
• Recognition
• 

  In the News

  • NOV 14, 2019

    Duke Health News

    Why a Leading Breast Cancer Treatment Works Is Still a Mystery. The Answer May Lead to New Therapies
• Research
• 

  Selected Grants

  • Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers awarded by National Institutes of Health 2019 - 2024
  • Viral Oncology Training Grant awarded by National Institutes of Health 1980 - 2024
  • Beyond PD1: An immunotherapeutic strategy to stimulate and enable both T-cell and B-cell responses in immunosuppressive and non-mutated metastatic breast cancer awarded by Department of Defense 2020 - 2024
  • Investigating the adaptive immune response to dormant tumor cells awarded by American Cancer Society, Inc. 2020 - 2023
  • Investigation of LAMP anti-tumor vaccines awarded by Immunomic Therapeutics, Inc. 2020 - 2022
  • Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2021
  • Investigation of stimulating stress response mechanisms to enhance antibody dependent cellular phagocytosis awarded by Bantam Pharmaceutical, LLC 2019 - 2021
  • A Neoepitope Subunit Vaccine Targeting the Mutated Estrogen Receptor Ligand Binding Domain to Treat and Prevent Endocrine Resistant ER+ Breast Cancer awarded by Department of Defense 2018 - 2021
  • Mechanisms of Action and Resistance to PD-1 Immunotherapies in Breast Cancer awarded by Merck 2017 - 2020
  • Detection and Elimination of Oncogenic Signaling Networks in Pre-malignant and Malignant Cells with Magnetic Resonance Imaging awarded by Department of Defense 2012 - 2020
  • Study of LAMP Vaccines in HER2+ Breast Cancer awarded by Immunomic Therapeutics, Inc. 2017 - 2020
  • Immunotherapeutic Targeting of a Therapy Resistant Oncogenic HER2 Isoform awarded by Susan G. Komen Breast Cancer Foundation 2017 - 2020
  • Investigating Adaptive Immune Recognition of Dormant Disseminated Tumor Cells awarded by Fred Hutchinson Cancer Research Center 2017 - 2019
  • Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
• 

  External Relationships

  • Bantam Pharmaceuticals
  • Replicate Biosciences, LLC
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Crosby, Erika J., Amy C. Hobeika, Donna Niedzwiecki, Christel Rushing, David Hsu, Peter Berglund, Jonathan Smith, et al. “Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio.” J Immunother Cancer 8, no. 2 (November 2020). https://doi.org/10.1136/jitc-2020-001662.
       Full Text  Link to Item
    • Crosby, Erika J., Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, et al. “Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.” Clin Cancer Res 26, no. 17 (September 1, 2020): 4670–81. https://doi.org/10.1158/1078-0432.CCR-20-0389.
       Full Text  Link to Item
    • Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils.” Cancer Res 80, no. 15 (August 1, 2020): 3088–3100. https://doi.org/10.1158/0008-5472.CAN-18-3825.
       Full Text  Link to Item
    • Chen, Alan Chen, Renhuan Xu, Tao Wang, Junping Wei, Xiao-Yi Yang, Cong-Xiao Liu, Gangjun Lei, Herbert Kim Lyerly, Teri Heiland, and Zachary Conrad Hartman. “HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression.” J Immunother Cancer 8, no. 1 (June 2020). https://doi.org/10.1136/jitc-2019-000258.
       Full Text  Link to Item
    • Tsao, Li-Chung, Erika J. Crosby, Timothy N. Trotter, Pankaj Agarwal, Bin-Jin Hwang, Chaitanya Acharya, Casey W. Shuptrine, et al. “CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis.” Jci Insight 4, no. 24 (December 19, 2019). https://doi.org/10.1172/jci.insight.131882.
       Full Text  Link to Item
    • Kula, Tomasz, Mohammad H. Dezfulian, Charlotte I. Wang, Nouran S. Abdelfattah, Zachary C. Hartman, Kai W. Wucherpfennig, Herbert Kim Lyerly, and Stephen J. Elledge. “T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes.” Cell 178, no. 4 (August 8, 2019): 1016-1028.e13. https://doi.org/10.1016/j.cell.2019.07.009.
       Full Text  Link to Item
    • Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.” Clin Cancer Res 25, no. 9 (May 1, 2019): 2725–36. https://doi.org/10.1158/1078-0432.CCR-18-3102.
       Full Text  Open Access Copy  Link to Item
    • Lyerly, H Kim, Takuya Osada, and Zachary C. Hartman. “Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy.” Clin Cancer Res 25, no. 1 (January 1, 2019): 9–11. https://doi.org/10.1158/1078-0432.CCR-18-2819.
       Full Text  Link to Item
    • Osada, Takuya, Zachary C. Hartman, Junping Wei, Gangjun Lei, Amy C. Hobeika, William R. Gwin, Marcio A. Diniz, et al. “Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.” Breast Cancer Res 20, no. 1 (August 9, 2018): 90. https://doi.org/10.1186/s13058-018-1023-x.
       Full Text  Link to Item
    • Crosby, Erika J., Junping Wei, Xiao Yi Yang, Gangjun Lei, Tao Wang, Cong-Xiao Liu, Pankaj Agarwal, et al. “Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.” Oncoimmunology 7, no. 5 (January 19, 2018): e1421891. https://doi.org/10.1080/2162402x.2017.1421891.
       Full Text
    • Osada, Takuya, Kensuke Kaneko, William R. Gwin, Michael A. Morse, Amy Hobeika, Brian W. Pogue, Zachary C. Hartman, Philip F. Hughes, Timothy Haystead, and H Kim Lyerly. “In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior.” Clin Cancer Res 23, no. 24 (December 15, 2017): 7531–42. https://doi.org/10.1158/1078-0432.CCR-17-1453.
       Full Text  Link to Item
    • Shuptrine, Casey W., Reham Ajina, Elana J. Fertig, Sandra A. Jablonski, H. Kim Lyerly, Zachary C. Hartman, and Louis M. Weiner. “An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.” Cancer Immunol Immunother 66, no. 12 (December 2017): 1529–44. https://doi.org/10.1007/s00262-017-2047-2.
       Full Text  Link to Item
    • Osada, Takuya, Michael A. Morse, Amy Hobeika, Marcio A. Diniz, William R. Gwin, Zachary Hartman, Junping Wei, et al. “Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.” Oncoimmunology 6, no. 6 (2017): e1315495. https://doi.org/10.1080/2162402X.2017.1315495.
       Full Text  Link to Item
    • Ren, Jun, William R. Gwin, Xinna Zhou, Xiaoli Wang, Hongyan Huang, Ni Jiang, Lei Zhou, et al. “Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.” Oncoimmunology 6, no. 4 (2017): e1264563. https://doi.org/10.1080/2162402X.2016.1264563.
       Full Text  Link to Item
    • Turpin, J., C. Ling, E. J. Crosby, Z. C. Hartman, A. M. Simond, L. A. Chodosh, J. P. Rennhack, et al. “The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.” Oncogene 35, no. 47 (November 24, 2016): 6053–64. https://doi.org/10.1038/onc.2016.129.
       Full Text  Link to Item
    • Mazumdar, Abhijit, Graham M. Poage, Jonathan Shepherd, Anna Tsimelzon, Zachary C. Hartman, Petra Den Hollander, Jamal Hill, et al. “Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.” Breast Cancer Res Treat 158, no. 3 (August 2016): 441–54. https://doi.org/10.1007/s10549-016-3892-y.
       Full Text  Link to Item
    • Zhao, Jing, Dekuang Zhao, Graham M. Poage, Abhijit Mazumdar, Yun Zhang, Jamal L. Hill, Zachary C. Hartman, Michelle I. Savage, Gordon B. Mills, and Powel H. Brown. “Death-associated protein kinase 1 promotes growth of p53-mutant cancers.” J Clin Invest 125, no. 7 (July 1, 2015): 2707–20. https://doi.org/10.1172/JCI70805.
       Full Text  Link to Item
    • Osada, Takuya, Koji Nagaoka, Masashi Takahara, Xiao Yi Yang, Cong-Xiao Liu, Hongtao Guo, Kingshuk Roy Choudhury, et al. “Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.” J Immunother 38, no. 4 (May 2015): 155–64. https://doi.org/10.1097/CJI.0000000000000075.
       Full Text  Link to Item
    • Barrott, Jared J., Philip F. Hughes, Takuya Osada, Xiao-Yi Yang, Zachary C. Hartman, David R. Loiselle, Neil L. Spector, et al. “Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.” Chem Biol 20, no. 9 (September 19, 2013): 1187–97. https://doi.org/10.1016/j.chembiol.2013.08.004.
       Full Text  Link to Item
    • Poage, Graham M., Zachary C. Hartman, and Powel H. Brown. “Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy.” Cell Cycle 12, no. 17 (September 1, 2013): 2705–6. https://doi.org/10.4161/cc.25871.
       Full Text  Link to Item
    • Hartman, Zachary C., Graham M. Poage, Petra den Hollander, Anna Tsimelzon, Jamal Hill, Nattapon Panupinthu, Yun Zhang, et al. “Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.” Cancer Research 73, no. 11 (June 2013): 3470–80. https://doi.org/10.1158/0008-5472.can-12-4524-t.
       Full Text
    • Kessler, J. D., K. T. Kahle, T. Sun, K. L. Meerbrey, M. R. Schlabach, E. M. Schmitt, S. O. Skinner, et al. “A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.” Science 335, no. 6066 (January 20, 2012): 348–53. https://doi.org/10.1126/science.1212728.
       Full Text
    • Hartman, Zachary C., Junping Wei, Oliver K. Glass, Hongtao Guo, Gangjun Lei, Xiao-Yi Yang, Takuya Osada, et al. “Increasing vaccine potency through exosome antigen targeting.” Vaccine 29, no. 50 (November 21, 2011): 9361–67. https://doi.org/10.1016/j.vaccine.2011.09.133.
       Full Text  Link to Item
    • Xia, Wenle, Zuguo Liu, Rongrong Zong, Leihua Liu, Sumin Zhao, Sarah S. Bacus, Yubin Mao, et al. “Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.” Mol Cancer Ther 10, no. 8 (August 2011): 1367–74. https://doi.org/10.1158/1535-7163.MCT-10-0991.
       Full Text  Link to Item
    • Hartman, Zachary C., Xiao-Yi Yang, Oliver Glass, Gangjun Lei, Takuya Osada, Sandeep S. Dave, Michael A. Morse, Timothy M. Clay, and Herbert K. Lyerly. “HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.” Cancer Res 71, no. 13 (July 1, 2011): 4380–91. https://doi.org/10.1158/0008-5472.CAN-11-0308.
       Full Text  Link to Item
    • Clay, Timothy M., Takuya Osada, Zachary C. Hartman, Amy Hobeika, Gayathri Devi, Michael A. Morse, and H Kim Lyerly. “Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.” Immunol Res 49, no. 1–3 (April 2011): 235–47. https://doi.org/10.1007/s12026-010-8186-6.
       Full Text  Link to Item
    • Hartman, Zachary C., Takuya Osada, Oliver Glass, Xiao Y. Yang, Gang-Jun Lei, H Kim Lyerly, and Timothy M. Clay. “Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.” Cancer Res 70, no. 18 (September 15, 2010): 7209–20. https://doi.org/10.1158/0008-5472.CAN-10-0905.
       Full Text  Link to Item
    • Seregin, Sergey S., Yasser A. Aldhamen, Daniel M. Appledorn, Zachary C. Hartman, Nathaniel J. Schuldt, Jeannine Scott, Sarah Godbehere, Haixiang Jiang, Michael M. Frank, and Andrea Amalfitano. “Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.” Blood 116, no. 10 (September 9, 2010): 1669–77. https://doi.org/10.1182/blood-2010-03-276949.
       Full Text  Link to Item
    • Gabitzsch, Elizabeth S., Younong Xu, Joseph P. Balint, Zachary C. Hartman, H Kim Lyerly, and Frank R. Jones. “Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.” Cancer Immunol Immunother 59, no. 7 (July 2010): 1131–35. https://doi.org/10.1007/s00262-010-0847-8.
       Full Text  Link to Item
    • Morse, Michael A., Junping Wei, Zachary Hartman, Wenle Xia, Xiu-Rong Ren, Gangjun Lei, William T. Barry, et al. “Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.” Int J Cancer 126, no. 12 (June 15, 2010): 2893–2903. https://doi.org/10.1002/ijc.24995.
       Full Text  Link to Item
    • Hartman, Zachary C., Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, et al. “An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.” Clin Cancer Res 16, no. 5 (March 1, 2010): 1466–77. https://doi.org/10.1158/1078-0432.CCR-09-2549.
       Full Text  Link to Item
    • Seregin, Sergey S., Zachary C. Hartman, Daniel M. Appledorn, Sarah Godbehere, Haixiang Jiang, Michael M. Frank, and Andrea Amalfitano. “Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor.” J Innate Immun 2, no. 4 (2010): 353–59. https://doi.org/10.1159/000284368.
       Full Text  Link to Item
    • Osada, T., X. Y. Yang, Z. C. Hartman, O. Glass, B. L. Hodges, D. Niedzwiecki, M. A. Morse, H. K. Lyerly, A. Amalfitano, and T. M. Clay. “Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.” Cancer Gene Ther 16, no. 9 (September 2009): 673–82. https://doi.org/10.1038/cgt.2009.17.
       Full Text  Link to Item
    • Osada, Takuya, Christopher Y. Woo, Matthew McKinney, Xiao Yi Yang, Gangjun Lei, Heather G. Labreche, Zachary C. Hartman, et al. “Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.” Clin Cancer Res 15, no. 8 (April 15, 2009): 2789–96. https://doi.org/10.1158/1078-0432.CCR-08-2589.
       Full Text  Link to Item
    • Cohen, Todd J., Tomasa Barrientos, Zachary C. Hartman, Sean M. Garvey, Gregory A. Cox, and Tso-Pang Yao. “The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity.” Faseb J 23, no. 1 (January 2009): 99–106. https://doi.org/10.1096/fj.08-115931.
       Full Text  Link to Item
    • Hartman, Zachary C., Daniel M. Appledorn, Delila Serra, Oliver Glass, Todd B. Mendelson, Timothy M. Clay, and Andrea Amalfitano. “Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.” Virology 374, no. 2 (May 10, 2008): 453–67. https://doi.org/10.1016/j.virol.2008.01.017.
       Full Text  Link to Item
    • Hartman, Zachary C., Daniel M. Appledorn, and Andrea Amalfitano. “Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.” Virus Res 132, no. 1–2 (March 2008): 1–14. https://doi.org/10.1016/j.virusres.2007.10.005.
       Full Text  Link to Item
    • Hartman, Zachary C., Esther P. Black, and Andrea Amalfitano. “Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells.” Virology 358, no. 2 (February 20, 2007): 357–72. https://doi.org/10.1016/j.virol.2006.08.041.
       Full Text  Link to Item
    • Hartman, Zachary C., Anne Kiang, Ruth S. Everett, Delila Serra, Xiao Y. Yang, Timothy M. Clay, and Andrea Amalfitano. “Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.” J Virol 81, no. 4 (February 2007): 1796–1812. https://doi.org/10.1128/JVI.01936-06.
       Full Text  Link to Item
    • Kiang, Anne, Zachary C. Hartman, Ruth S. Everett, Delila Serra, Haixiang Jiang, Michael M. Frank, and Andrea Amalfitano. “Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.” Mol Ther 14, no. 4 (October 2006): 588–98. https://doi.org/10.1016/j.ymthe.2006.03.024.
       Full Text  Link to Item
    • Kiang, Anne, Zachary C. Hartman, Shaoxi Liao, Fang Xu, Delila Serra, Donna J. Palmer, Philip Ng, and Andrea Amalfitano. “Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice.” Mol Ther 13, no. 1 (January 2006): 127–34. https://doi.org/10.1016/j.ymthe.2005.08.006.
       Full Text  Link to Item

  • Conference Papers

    • Tsao, Li-Chung, Jun-Ping Wei, Gang-jun Lei, Tao Wang, Xiao-Yi Yang, Cong-Xiao Liu, H Kim Lyerly, and Zachary C. Hartman. “Abstract 3955: Tumor macrophage-mediated antibody dependent cell phagocytosis (ADCP) is theprimary mechanism mediating HER2 mAb (Trastuzumab) anti-tumor responses which can be synergistically enhanced by CD47 innate immune checkpoint blockade.” In Immunology. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.sabcs18-3955.
       Full Text
    • Crosby, E. J., W. R. Gwin, S. Chang, H. T. Maecker, V. Lubkov, J. C. Snyder, G. Broadwater, et al. “Abstract P2-09-16: CD8 T cells induced by novel alphaviral vector predict improved progression free survival in advanced HER2+ breast cancer patients.” In Poster Session Abstracts. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.sabcs18-p2-09-16.
       Full Text
    • Crosby, Erika J., Gangjun Lei, Junping Wei, Xiao Yi Yang, Tao Wang, Cong-Xiao Liu, H Kim Lyerly, and Zachary C. Hartman. “Abstract A22: Augmentation of a novel adenoviral vaccine strategy by checkpoint inhibitors.” In Checkpoints and Immunomodulation. American Association for Cancer Research, 2018. https://doi.org/10.1158/2326-6074.tumimm17-a22.
       Full Text
    • Crosby, Erika J., Junping Wei, Xiao Yi Yang, Gangjun Lei, Tao Wang, Cong-Xiao Liu, Pankaj Agarwal, H Kim Lyerly, and Zachary C. Hartman. “Abstract A38: Checkpoint blockade elicits unique T cell expansion to promote tumor regression.” In Immunomodulation. American Association for Cancer Research, 2017. https://doi.org/10.1158/2326-6074.tumimm16-a38.
       Full Text
    • Hartman, Z. C., E. J. Crosby, J. -. P. Wei, X. -. Y. Yang, G. -. J. Lei, T. Wang, C. -. X. Liu, P. Agarwal, M. S. Morse, and H. K. Lyerly. “Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer.” In Poster Session Abstracts. American Association for Cancer Research, 2017. https://doi.org/10.1158/1538-7445.sabcs16-p2-04-27.
       Full Text
    • Kessler, Jessica D., Kristopher T. Kahle, Tingting Sun, Kristen L. Meerbrey, Michael R. Schlabach, Earlene M. Schmitt, Samuel O. Skinner, et al. “A sumoylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.” In Cancer Research, Vol. 72, 2012. https://doi.org/10.1158/1538-7445.AM2012-3091.
       Full Text  Link to Item
    • Seregin, Sergey S., Zachary C. Hartman, Daniel M. Appledorn, Yasser A. Aldhamen, Nathaniel J. Schuldt, Mathew Bujold, Sarah Godbehere, and Andrea Amalfitano. “Improved Safety Profile of Novel Adenovirus Based Vectors "Capsid-displaying" Complement Inhibitors: Increased Potential for Cardiovascular Gene Transfer Applications.” In Circulation, 120:S899–900. LIPPINCOTT WILLIAMS & WILKINS, 2009.
       Link to Item
    • Osada, Takuya, Heather Labreche, Zachery C. Hartman, Delila Serra, Michael A. Morse, H Kim Lyerly, Andrea Amalfitano, and Timothy M. Clay. “Replication-competent packaging-deficient [E1+, 100k-] adenoviral vector-transduced dendritic cells can efficiently induce antigen-specific immune responses.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.
       Link to Item
    • Woo, Christopher Y., Takuya Osada, Xiao Yi Yang, Gangjun Lei, Matthew McKinney, Heather Labreche, Zachary C. Hartman, et al. “Induction of Wilms' tumor protein (WT1)-specific immunity using a WT1-expressing adenovirus vaccine.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.
       Link to Item
    • Hartman, Zachary C., Todd Mendelson, and Andrea Amalfitano. “19. A New, Plasmid-Based Adenoviral Vectoring System Derived from the Highly Immunogenic, Human Ad4 Strain.” In Molecular Therapy, 13:S8–S8. Elsevier BV, 2006. https://doi.org/10.1016/j.ymthe.2006.08.030.
       Full Text
• Teaching & Mentoring
• 

  Recent Courses

  • PATHOL 793: Research Independent Study 2020
  • PATHOL 793: Research Independent Study 2019

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.